N-monomethyl-L-arginine: Phase II

Copenhagen researchers published in The Lancet results with 6 mg/kg L-NMMA versus placebo in 16 patients with chronic tension-type headache. The crossover trial measured headache intensity on a visual analog scale. Two hours post-treatment, L-NMMA reduced pain to 33 points from 49 points versus a reduction to 40 points from 44 points with placebo (p=0.01). The researchers concluded that inhibition of NOS has an analgesic effect in these patients, validating NOS as a target in this indication. ...